ClinicalTrials.Veeva

Menu

Efficacy of Zinc Supplementation on Botox Treated Forehead Rhytids

University of New Mexico (UNM) logo

University of New Mexico (UNM)

Status

Withdrawn

Conditions

Adjuvant Zinc May Increase the Efficacy of Botulinum Toxin
Zinc Supplementation for Botulinum Toxin Treatment of the Forehead
Glabellar Frown Lines
Botulinum Toxin, Cosmetic
Adjuvant Oral Zinc and Botulinum Toxin

Treatments

Dietary Supplement: zinc citrate 50 mg
Other: Placebo Microcrystalline Cellulose

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT05894109
STUDY00006041

Details and patient eligibility

About

The current literature suggests that zinc supplementation may increase the duration of botulinum toxin; however, each study had their limitations. Further, no one has studied the effect of zinc supplementation for botulinum toxin treatment of the forehead. The purpose of this study is to evaluate the effect of zinc supplementation on frontalis muscle denervation by objectively assessing the degree of forehead rhytids and movement of the eyebrows.

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Any patient older than 18 years old who desires botulinum toxin injection to decrease forehead rhytids

Exclusion criteria

  • Allergy to any components of zinc citrate or botulinum toxin
  • inflammation or infection at site of injection
  • patients using anticholineresterase or other agents interfering with neuromuscular transmission
  • patients with any medical condition that can affect frontalis function (Bell's palsy, Möbius syndrome, Hemifacial microsomia, CHARGE syndrome, stroke, etc)
  • patients with any prior trauma that could have potentially injured the frontalis muscle
  • patients dependent on intact facial movements and expressions for their livelihood (actors, singers, musicians, etc)

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

0 participants in 2 patient groups, including a placebo group

OnabotulinumtoxinA without Zinc Supplementation
Placebo Comparator group
Description:
Given placebo
Treatment:
Other: Placebo Microcrystalline Cellulose
OnabotulinumtoxinA with Zinc Supplementation
Experimental group
Description:
Given 50 mg of zinc citrate
Treatment:
Dietary Supplement: zinc citrate 50 mg

Trial contacts and locations

0

Loading...

Central trial contact

Jeffrey Wu, MD; Addi Moya, BS

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems